NASDAQ:QURE

uniQure Competitors

$32.21
-0.30 (-0.92 %)
(As of 04/21/2021 02:33 PM ET)
Add
Compare
Today's Range
$31.61
Now: $32.21
$32.58
50-Day Range
$29.24
MA: $33.44
$38.05
52-Week Range
$28.58
Now: $32.21
$71.45
Volume5,505 shs
Average Volume460,722 shs
Market Capitalization$1.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19

Competitors

uniQure (NASDAQ:QURE) Vs. IONS, SRPT, TGTX, PRGO, ALLK, and BPMC

Should you be buying QURE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to uniQure, including Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), TG Therapeutics (TGTX), Perrigo (PRGO), Allakos (ALLK), and Blueprint Medicines (BPMC).

Ionis Pharmaceuticals (NASDAQ:IONS) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 78.3% of uniQure shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Earnings and Valuation

This table compares Ionis Pharmaceuticals and uniQure's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.12 billion5.21$303.26 million$2.0819.97
uniQure$7.28 million199.07$-124,200,000.00($3.11)-10.36

Ionis Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and uniQure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ionis Pharmaceuticals7.82%6.57%3.39%
uniQure-2,738.33%-59.64%-41.47%

Analyst Ratings

This is a breakdown of current ratings and target prices for Ionis Pharmaceuticals and uniQure, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ionis Pharmaceuticals27602.27
uniQure011113.00

Ionis Pharmaceuticals currently has a consensus price target of $57.4545, suggesting a potential upside of 38.54%. uniQure has a consensus price target of $68.4615, suggesting a potential upside of 115.49%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats uniQure on 9 of the 15 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Volatility and Risk

uniQure has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Institutional and Insider Ownership

78.3% of uniQure shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 2.8% of uniQure shares are owned by company insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares uniQure and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
uniQure-2,738.33%-59.64%-41.47%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Earnings and Valuation

This table compares uniQure and Sarepta Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$7.28 million199.07$-124,200,000.00($3.11)-10.36
Sarepta Therapeutics$380.83 million15.06$-715,080,000.00($9.71)-7.44

uniQure has higher earnings, but lower revenue than Sarepta Therapeutics. uniQure is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for uniQure and Sarepta Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
uniQure011113.00
Sarepta Therapeutics191302.52

uniQure presently has a consensus target price of $68.4615, suggesting a potential upside of 115.49%. Sarepta Therapeutics has a consensus target price of $150.3810, suggesting a potential upside of 107.88%. Given uniQure's stronger consensus rating and higher probable upside, research analysts clearly believe uniQure is more favorable than Sarepta Therapeutics.

Summary

uniQure beats Sarepta Therapeutics on 8 of the 15 factors compared between the two stocks.

TG Therapeutics (NASDAQ:TGTX) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

65.7% of TG Therapeutics shares are owned by institutional investors. Comparatively, 78.3% of uniQure shares are owned by institutional investors. 13.2% of TG Therapeutics shares are owned by insiders. Comparatively, 2.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

TG Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for TG Therapeutics and uniQure, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TG Therapeutics01502.83
uniQure011113.00

TG Therapeutics currently has a consensus price target of $63.3333, suggesting a potential upside of 56.57%. uniQure has a consensus price target of $68.4615, suggesting a potential upside of 115.49%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than TG Therapeutics.

Profitability

This table compares TG Therapeutics and uniQure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TG Therapeutics-151,798.69%-223.96%-108.08%
uniQure-2,738.33%-59.64%-41.47%

Earnings & Valuation

This table compares TG Therapeutics and uniQure's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$150,000.0038,080.06$-172,870,000.00($1.83)-22.20
uniQure$7.28 million199.07$-124,200,000.00($3.11)-10.36

uniQure has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Summary

uniQure beats TG Therapeutics on 11 of the 15 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Institutional and Insider Ownership

78.3% of uniQure shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 2.8% of uniQure shares are held by insiders. Comparatively, 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

uniQure has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for uniQure and Perrigo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
uniQure011113.00
Perrigo03102.25

uniQure presently has a consensus price target of $68.4615, suggesting a potential upside of 115.49%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 22.09%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Perrigo.

Profitability

This table compares uniQure and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
uniQure-2,738.33%-59.64%-41.47%
Perrigo-0.13%9.78%4.92%

Earnings & Valuation

This table compares uniQure and Perrigo's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$7.28 million199.07$-124,200,000.00($3.11)-10.36
Perrigo$4.84 billion1.18$146.10 million$4.0310.56

Perrigo has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Summary

uniQure beats Perrigo on 8 of the 15 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and target prices for uniQure and Allakos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
uniQure011113.00
Allakos00403.00

uniQure presently has a consensus price target of $68.4615, suggesting a potential upside of 115.49%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 71.26%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Allakos.

Institutional and Insider Ownership

78.3% of uniQure shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 2.8% of uniQure shares are held by insiders. Comparatively, 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

uniQure has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Earnings & Valuation

This table compares uniQure and Allakos' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$7.28 million199.07$-124,200,000.00($3.11)-10.36
AllakosN/AN/A$-85,370,000.00($1.89)-56.07

Allakos has lower revenue, but higher earnings than uniQure. Allakos is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares uniQure and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
uniQure-2,738.33%-59.64%-41.47%
AllakosN/A-29.18%-27.70%

Summary

uniQure beats Allakos on 7 of the 13 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Volatility & Risk

Blueprint Medicines has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Blueprint Medicines and uniQure, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06812.67
uniQure011113.00

Blueprint Medicines presently has a consensus target price of $112.40, suggesting a potential upside of 19.36%. uniQure has a consensus target price of $68.4615, suggesting a potential upside of 115.49%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Blueprint Medicines.

Earnings and Valuation

This table compares Blueprint Medicines and uniQure's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million81.93$-347,690,000.00($7.27)-12.93
uniQure$7.28 million199.07$-124,200,000.00($3.11)-10.36

uniQure has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

78.3% of uniQure shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by company insiders. Comparatively, 2.8% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Blueprint Medicines and uniQure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
uniQure-2,738.33%-59.64%-41.47%

Summary

uniQure beats Blueprint Medicines on 8 of the 14 factors compared between the two stocks.


uniQure Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.53-0.9%$5.80 billion$1.12 billion86.52Analyst Report
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$72.22-1.3%$5.66 billion$380.83 million-9.24Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$40.63-1.6%$5.62 billion$150,000.00-19.17Analyst Report
Analyst Revision
News Coverage
Gap Up
Perrigo logo
PRGO
Perrigo
2.3$42.57-1.2%$5.62 billion$4.84 billion-709.38Dividend Announcement
Allakos logo
ALLK
Allakos
1.7$105.98-1.7%$5.57 billionN/A-38.68
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.02-1.5%$5.37 billion$66.51 million17.35Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$82.80-3.8%$5.22 billion$1.00 billion-12.55Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.5$72.68-3.6%$4.90 billion$85.54 million0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.58-1.2%$4.57 billionN/A-6.08Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.04-0.8%$4.29 billion$6.87 million-7.15Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.79-2.7%$4.22 billion$204.89 million-37.24
I-Mab logo
IMAB
I-Mab
1.4$55.56-2.3%$4.09 billion$4.31 million-1.92
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.77-1.5%$4.03 billion$806.43 million-9.60Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.10-1.1%$3.89 billion$117.91 million-11.18
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.97-0.0%$3.70 billionN/A-6.20
LEGN
Legend Biotech
1.2$27.16-1.6%$3.55 billion$64.39 million0.00Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$66.00-0.6%$3.52 billion$1.11 billion21.22News Coverage
Gap Up
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.31-2.4%$3.50 billionN/A-20.89
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$40.95-3.4%$3.50 billionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.70-4.5%$3.43 billion$114.62 million-7.94
Insmed logo
INSM
Insmed
1.2$33.55-3.7%$3.34 billion$136.47 million-12.90
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.40-2.8%$3.33 billion$339.08 million-12.44Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$45.72-1.3%$3.26 billion$306.98 million-6.54
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.52-1.4%$3.23 billion$26.52 million-7.98Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.51-1.7%$3.21 billion$1.17 billion-44.59Insider Selling
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.05-1.7%$3.16 billion$36.13 million-68.73
Arvinas logo
ARVN
Arvinas
1.5$65.60-5.6%$3.03 billion$42.98 million-25.63Upcoming Earnings
Analyst Report
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.75-1.1%$2.96 billion$80.43 million108.34
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$108.44-0.4%$2.92 billionN/A-53.95News Coverage
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$76.68-0.9%$2.91 billion$644.77 million-10.94
OPKO Health logo
OPK
OPKO Health
1.9$4.28-3.5%$2.77 billion$901.90 million-23.78
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$64.21-2.4%$2.75 billion$421.03 million22.61News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.32-1.3%$2.65 billion$25 million-9.06Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.04-2.2%$2.64 billion$306.49 million25.89
Organogenesis logo
ORGO
Organogenesis
1.0$21.25-3.5%$2.62 billion$260.98 million-354.17News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$42.87-1.3%$2.61 billionN/A-23.55
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.92-1.4%$2.59 billion$182.24 million-8.63Analyst Upgrade
Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$42.15-2.1%$2.57 billion$2.11 million-9.12Analyst Report
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$29.55-3.4%$2.47 billion$60,000.00-9.18Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.54-2.5%$2.44 billion$120.28 million-152.06Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$41.95-1.0%$2.41 billion$156.70 million-29.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.47-3.4%$2.32 billion$23.90 million-18.30Analyst Report
Insider Selling
Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$33.68-5.1%$2.26 billion$15 million-17.63
Cryoport logo
CYRX
Cryoport
1.7$51.74-4.1%$2.26 billion$33.94 million-89.21
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.74-1.3%$2.25 billion$963.01 million14.20
ALX Oncology logo
ALXO
ALX Oncology
1.9$56.50-3.6%$2.18 billionN/A0.00
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$52.65-2.8%$2.10 billionN/A0.00Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.60-2.5%$2.02 billionN/A-11.71News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$33.84-0.5%$2.02 billion$64.19 million-10.81Analyst Report
Insider Selling
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.79-3.7%$1.98 billion$103.54 million-20.14
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.